Claims for Patent: 7,026,330

Summary for Patent: 7,026,330

Title:	Methods for treatment of acute lymphocytic leukemia
Abstract:	Methods for treating patients having an early B cell derived acute lymphoblastic leukemia with rapamycin or a derivative thereof are provided. Also provided are methods for treating patients having an early B cell derived acute lymphoblastic leukemia with rapamycin or a derivative thereof in combination with an IL-7 inhibitor. Finally methods for preventing GVHD in ALL patients following a bone marrow transplant are disclosed.
Inventor(s):	Grupp; Stephan A. (Havertown, PA), Brown; Valerie I. (Philadelphia, PA)
Assignee:	The Children\'s Hospital of Philadelphia (Philadelphia, PA)
Application Number:	10/453,056
Patent Claims:	1. A method for treating a patient having an early B cell acute lymphoblastic leukemia (ALL) comprising administering to said patient a therapeutically effective amount of rapamycin or a derivative thereof and a therapeutically effective amount of an IL-7 inhibitor, wherein said rapamycin or derivative thereof inhibits the mammalian target of rapamycin (mTOR). 2. The method of claim 1, wherein said patient is newly diagnosed with early B cell ALL. 3. The method of claim 1, wherein said patient is experiencing refractory or relapsed early B cell ALL. 4. The method of claim 1, wherein said rapamycin or derivative thereof and said IL-7 inhibitor are administered, simultaneously or sequentially. 5. The method of claim 1, wherein said IL-7 inhibitor is an IL-7 specific antibody or a fragment thereof. 6. The method of claim 1, further comprising administering at least one anti-cancer agent selected from the group consisting of alkylating agents, bifunctional alkylating agents, non-steroidal aromatase inhibitors, immunotherapeutic agents, nitrosurea compounds, antimetabolites, antitumor antibiotics, mitotic inhibitors, radiation, topoisomerase I inhibitors, and anti-estrogens. 7. The method of claim 1, further comprising administering at least one anti-cancer agent selected from the group consisting of cisplatin, carboplatin, oxaliplatin, radiation, CPT-11, paclitaxel, 5-flourouracil, leucovorin, epothilone, gemcitabine, UFT, herceptin, cytoxan, dacarbaxine, ifosfamide, mechlorethamine, melphalan, chlorambucil, anastrozole, exemstane, carmustine, lomustine, methotrexate, gemcitabine, cytarabine, fludarabine, bleomycin, dactinomycin, daunorubicin, doxorubicin, idarubicin, docetaxel, vinblastine, vincristin, vinorelbine, topotecan, lupron, megace, leucovorin, Iressa, flavopiridol, immunomotherapeutic agents, ZD6474, SU6668, and valspodar. 8. The method of claim 1, wherein said patient is experiencing refractory or relapsed early B-cell ALL following a bone marrow transplant (BMT), and wherein said administration of a therapeutically effective amount of rapamycin or a derivative thereof inhibits graft versus host disease. 9. The method of claim 8, wherein said rapamycin is administered in combination with at least one other immunosuppression agent. 10. The method of claim 8, wherein said rapamycin or a derivative thereof is administered post said BMT. 11. The method of claim 8, further comprising administering to said patient a therapeutic effective amount of at least one immunosuppressant prior and/or post said BMT.

Details for Patent 7,026,330

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2022-05-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2022-05-30